Virtu Financial LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 24,718 shares of the company’s stock, valued at approximately $368,000.
A number of other institutional investors also recently made changes to their positions in the business. One Fin Capital Management LP bought a new position in Elanco Animal Health during the 4th quarter worth approximately $6,109,000. Point72 Europe London LLP purchased a new stake in shares of Elanco Animal Health during the fourth quarter valued at approximately $804,000. Wolf Hill Capital Management LP bought a new position in shares of Elanco Animal Health in the fourth quarter worth approximately $20,683,000. Lighthouse Investment Partners LLC purchased a new position in shares of Elanco Animal Health in the fourth quarter worth $3,136,000. Finally, Pinebridge Investments L.P. increased its stake in shares of Elanco Animal Health by 65.6% in the fourth quarter. Pinebridge Investments L.P. now owns 73,278 shares of the company’s stock worth $1,092,000 after buying an additional 29,040 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.
Elanco Animal Health Price Performance
Shares of ELAN stock opened at $18.16 on Thursday. The business’s fifty day moving average is $15.98 and its 200 day moving average is $15.49. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.95. The stock has a market cap of $8.97 billion, a price-to-earnings ratio of -6.85, a PEG ratio of 1.76 and a beta of 1.45. Elanco Animal Health Incorporated has a twelve month low of $8.52 and a twelve month high of $18.80.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.08. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same period in the prior year, the firm earned $0.45 EPS. The company’s revenue was down 4.1% compared to the same quarter last year. Research analysts expect that Elanco Animal Health Incorporated will post 0.93 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. TheStreet raised shares of Elanco Animal Health from a “d+” rating to a “c-” rating in a report on Friday, February 23rd. The Goldman Sachs Group raised their target price on Elanco Animal Health from $12.50 to $14.00 and gave the stock a “sell” rating in a research note on Tuesday, February 27th. Morgan Stanley upped their price target on Elanco Animal Health from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Piper Sandler reiterated a “neutral” rating and issued a $19.00 price objective (up from $18.00) on shares of Elanco Animal Health in a research report on Monday, May 13th. Finally, Barclays upped their target price on Elanco Animal Health from $19.00 to $23.00 and gave the company an “overweight” rating in a report on Thursday, May 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Elanco Animal Health presently has an average rating of “Moderate Buy” and a consensus price target of $18.29.
View Our Latest Research Report on Elanco Animal Health
Insider Transactions at Elanco Animal Health
In related news, Director William F. Doyle acquired 15,000 shares of Elanco Animal Health stock in a transaction that occurred on Tuesday, May 21st. The stock was bought at an average price of $16.98 per share, with a total value of $254,700.00. Following the transaction, the director now directly owns 76,330 shares in the company, valued at $1,296,083.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.57% of the company’s stock.
Elanco Animal Health Profile
(Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Further Reading
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.